Oranda Therapeutics Ltd

Oranda Therapeutics Limited is an Irish-headquartered rare disease company dedicated to improving sustainable access to established and innovative new medicines across Europe. The company focuses on rare cardio-respiratory conditions, specifically idiopathic pulmonary fibrosis, hereditary amyloidosis and cystic fibrosis, though it considers itself therapy area agnostic. It works to address the fact that fewer than half of all EMA approved innovative medicines are available to rare disease patients throughout Europe, with affordability a critical barrier. Oranda provides affordable, high quality, essentially similar versions of established rare disease medicines on Loss of Exclusivity, and collaborates with system stakeholders to address access barriers. Founded on partnership, the company is entrepreneurial and agile, serving patients, customers and partners across 27 EU markets.